Close Menu

NEW YORK – Roche announced Friday that its Cobas SARS-CoV-2 & Influenza A/B test received Emergency Use Authorization from the US Food and Drug Administration. 

The RT-PCR test runs on Roche's Cobas 6800/8800 systems and is intended to qualitatively detect and differentiate SARS-CoV-2, influenza A, and influenza B from one nasal or nasopharyngeal sample. The multiplex test is also available in countries accepting the CE mark.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.